CA-125 Strategy Cuts Death, Readmission in Heart Failure

Share this content:
CA-125 Strategy Cuts Death, Readmission in Heart Failure
CA-125 Strategy Cuts Death, Readmission in Heart Failure

THURSDAY, Aug. 11, 2016 (HealthDay News) -- For patients discharged with acute heart failure (AHF), antigen carbohydrate 125-guided therapy (CA125-strategy) is associated with a significant reduction in the risk of one-year death or readmission for AHF, according to a study published online Aug. 10 in JACC: Heart Failure.

Julio Núñez, M.D., from the Universitat de Valencia in Spain, and colleagues conducted a multicenter randomized trial involving 380 patients discharged for AHF and high CA125. Patients were randomized to a CA125-strategy (187 patients) or standard of care (SOC; 193 patients), with the aim of CA125-strategy to reduce CA125 to ≤35 U/ml.

The researchers found that patients assigned to the CA125-strategy were more often visited and treated with ambulatory intravenous loop diuretics and statins; oral loop diuretic and aldosterone receptor blocker doses were more frequently modified. CA125 was associated with a significant reduction in the primary end point of one-year composite of death/AHF readmission, as a first event (P = 0.017) or as recurrent events (P = 0.008). A significant reduction in rehospitalizations, but not mortality, was the driver of the effect.

"CA125-strategy was superior to SOC in terms of reducing the risk of the composite of one-year death/AHF-readmission," the authors write. "This effect was mainly driven by significantly reducing the rate of rehospitalizations."

One author disclosed financial ties to Servier and Ferrer.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Artificial Intelligence Promising for CA, Retinopathy Diagnoses

Artificial Intelligence Promising for CA, Retinopathy Diagnoses

Two studies evaluate use; one for breast cancer, the other for diabetic retinopathy

USPSTF Recommends Against Hormone Tx Post Menopause

USPSTF Recommends Against Hormone Tx Post Menopause

Benefits do not outweigh harms of using hormone therapy for prevention of chronic conditions

Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

Findings in multifood allergic pediatric patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »